These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 19379084)

  • 21. Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers.
    Deng D; Liu Z; Du Y
    Adv Genet; 2010; 71():125-76. PubMed ID: 20933128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant promoter hypermethylation in biliary tract carcinoma.
    Kohya N; Koga Y; Kitajima Y; Miyazaki K
    J Hepatobiliary Pancreat Surg; 2006; 13(4):296-305. PubMed ID: 16858540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detecting recurrent bladder cancer: new methods and biomarkers.
    Ross JS; Cohen MB
    Expert Rev Mol Diagn; 2001 May; 1(1):39-52. PubMed ID: 11901799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of PMF1 methylation in association with bladder cancer progression.
    Aleman A; Cebrian V; Alvarez M; Lopez V; Orenes E; Lopez-Serra L; Algaba F; Bellmunt J; López-Beltrán A; Gonzalez-Peramato P; Cordon-Cardo C; García J; del Muro JG; Esteller M; Sánchez-Carbayo M
    Clin Cancer Res; 2008 Dec; 14(24):8236-43. PubMed ID: 19088041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of myopodin methylation in bladder cancer.
    Cebrian V; Alvarez M; Aleman A; Palou J; Bellmunt J; Gonzalez-Peramato P; Cordón-Cardo C; García J; Piulats JM; Sánchez-Carbayo M
    J Pathol; 2008 Sep; 216(1):111-9. PubMed ID: 18636402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic tumor markers in plasma and serum: biology and applications to molecular diagnosis and disease monitoring.
    Wong IH; Lo YM; Johnson PJ
    Ann N Y Acad Sci; 2001 Sep; 945():36-50. PubMed ID: 11708493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In search of the perfect crystal ball for Ta urothelial cancer.
    Chin JL
    Eur Urol; 2010 Jan; 57(1):21-2; discussion 23-4. PubMed ID: 19748172
    [No Abstract]   [Full Text] [Related]  

  • 28. Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers.
    Oliveira AI; Jerónimo C; Henrique R
    Expert Rev Mol Diagn; 2012 Nov; 12(8):871-8. PubMed ID: 23249204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA methylation and cancer diagnosis: new methods and applications.
    Dehan P; Kustermans G; Guenin S; Horion J; Boniver J; Delvenne P
    Expert Rev Mol Diagn; 2009 Oct; 9(7):651-7. PubMed ID: 19817550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High frequency of promoter methylation of the 14-3-3 sigma and CAGE-1 genes, but lack of hypermethylation of the caveolin-1 gene, in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder.
    Kunze E; Schlott T
    Int J Mol Med; 2007 Oct; 20(4):557-63. PubMed ID: 17786288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylation profiling of human cancers in blood: molecular monitoring and prognostication (review).
    Wong IH
    Int J Oncol; 2001 Dec; 19(6):1319-24. PubMed ID: 11713606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of epigenetic alterations in pancreatic cancer.
    Sato N; Goggins M
    J Hepatobiliary Pancreat Surg; 2006; 13(4):286-95. PubMed ID: 16858539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of diagnostic and prognostic markers in urothelial carcinoma of the bladder.
    Coleman JF; Hansel DE
    Adv Anat Pathol; 2009 Mar; 16(2):67-78. PubMed ID: 19550368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
    Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
    Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of DNA methylation for cancer detection: promises and challenges.
    Zhu J; Yao X
    Int J Biochem Cell Biol; 2009 Jan; 41(1):147-54. PubMed ID: 18834953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carcinogen exposure and epigenetic silencing in bladder cancer.
    Marsit CJ; Karagas MR; Schned A; Kelsey KT
    Ann N Y Acad Sci; 2006 Sep; 1076():810-21. PubMed ID: 17119258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
    Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
    Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
    Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
    Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
    Baylin SB; Ohm JE
    Nat Rev Cancer; 2006 Feb; 6(2):107-16. PubMed ID: 16491070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.